MiDx uses unique biomarkers produced by microbes for detection in clinical samples. These biomarkers are present in multiple biofluids allowing for non-microbial containing samples to be used in a POC device. Our lead product uses unique biomarkers for Pseudomonas aeruginosa to detect this bacterium in multiple biofluids (blood, plasma, urine and saliva). This is of particular importance in respiratory infections in people with chronic disease e.g. Cystic fibrosis, where new modulator therapies have markedly changed the production of sputum meaning sputum culture is exceptional challenging.
| Website | http://www.mi-dx.com |
| Employees | 5 (1 on RocketReach) |
| Founded | 2023 |
| Industry | Biotechnology Research |
| Keywords | Point Of Care Diagnostics, Biomarker Detection, Poc Diagnostics, Diagnostic Biomarkers, Clinical Diagnostics, Disease Detection, Diagnostic Testing, Medical Diagnostics, Early Disease Detection, Rapid Diagnostics, Microbial Identification, Molecular Diagnostics, Infectious Disease Diagnostics, Sample Analysis, In Vitro Diagnostics, Microbiome Analysis, Clinical Microbiology |
Looking for a particular MiDx Ltd employee's phone or email?
MiDx Ltd Questions
Simone Lucanto is the CTO of MiDx Ltd.
1 people are employed at MiDx Ltd.
Top MiDx Ltd Employees
